Supernus Pharmaceuticals, Inc. (SUPN) Stake Lifted by Rhumbline Advisers

Rhumbline Advisers lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,757 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,850 shares during the quarter. Rhumbline Advisers owned 0.19% of Supernus Pharmaceuticals worth $3,870,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Neumeier Poma Investment Counsel LLC raised its stake in shares of Supernus Pharmaceuticals by 1.6% in the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after purchasing an additional 14,430 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Supernus Pharmaceuticals by 6.9% in the second quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock worth $20,087,000 after acquiring an additional 29,939 shares during the period. Royce & Associates LP grew its holdings in shares of Supernus Pharmaceuticals by 22.3% in the second quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock worth $6,853,000 after acquiring an additional 29,000 shares during the period. Scout Investments Inc. grew its holdings in shares of Supernus Pharmaceuticals by 2.6% in the second quarter. Scout Investments Inc. now owns 166,675 shares of the specialty pharmaceutical company’s stock worth $7,184,000 after acquiring an additional 4,225 shares during the period. Finally, Royal Bank of Canada grew its holdings in shares of Supernus Pharmaceuticals by 790.8% in the second quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after acquiring an additional 240,978 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $47.60, for a total transaction of $2,380,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the sale, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $623,250. The disclosure for this sale can be found here. Insiders own 6.70% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) opened at $36.45 on Thursday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $21.60 and a fifty-two week high of $50.04. The stock has a market capitalization of $1,901.82, a PE ratio of 35.00, a price-to-earnings-growth ratio of 1.57 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. The company’s quarterly revenue was up 41.5% compared to the same quarter last year. equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.07 earnings per share for the current fiscal year.

Several analysts recently commented on the company. Stifel Nicolaus lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price objective for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Janney Montgomery Scott reaffirmed a “hold” rating and issued a $47.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $45.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. Cowen set a $50.00 price objective on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $49.60.

COPYRIGHT VIOLATION WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Stake Lifted by Rhumbline Advisers” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/12/07/supernus-pharmaceuticals-inc-supn-stake-lifted-by-rhumbline-advisers.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply